Recently updated international guidelines recommend a more prominent role for multiparametric magnetic resonance imaging (mpMRI) in the work-up for prostate cancer (PCa) diagnosis [1,2]. However, the benefit of dynamic contrast-enhanced (DCE) MRI for PCa detection and localization is still a matter of debate. Omitting DCE may improve MRI accessibility in response to the increasing demand for this imaging modality. A so-called biparametric MRI (bpMRI) protocol only uses T2-weighted and diffusion-weighted imaging.